title: Phase II trial with oral idarubicin in advanced breast cancer.
abstract: Idarubicin, a new analogue of daunorubicin, was administered to 27 patients with advanced breast cancer in a phase II trial. The drug was given orally at a dose of 30-35 mg/m2 every 3 weeks. Twenty-two patients were evaluable for response. All evaluable patients were previously treated with one or more chemotherapeutic regimens, including an anthracycline in more than 50% of the cases. Partial remissions were obtained in 5 patients, for a response rate of 23%. The median duration of response was 191 days. Mild nausea and vomiting were common. Diarrhea, which occurred in less than 50% of the patients, was usually short-lived. Alopecia was generally minimal. Myelosuppression was the dose-limiting toxic effect. Leukopenia was frequently seen, with full recovery by day 28 in 81% of the courses. Thrombocytopenia was less common than leukopenia. Four cases of grade 1 acute cardiac toxicity were recorded. This study suggests that idarubicin can induce regressions in advanced carcinoma of the breast, and justifies further studies in combination with other agents.
authors.forename: M
authors.initials: M
authors.lastname: Lopez
authors.forename: L
authors.initials: L
authors.lastname: Di Lauro
authors.forename: P
authors.initials: P
authors.lastname: Papaldo
authors.forename: B
authors.initials: B
authors.lastname: Lazzaro
authors.forename: F
authors.initials: F
authors.lastname: Ganzina
authors.forename: N
authors.initials: N
authors.lastname: Di Pietro
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D015255:Idarubicin; D003630:Daunorubicin